Clinical and metabolic effects of Gynodian-depot in vegetoneurotic disorders following removal of uterine myoma in menopausal patients.
Clinical and metabolic effects of depot-injections of estradiol valerianate-dehydroepiandrosterone enanthate at a 1:50 ratio (Gynodian-depot) in the treatment of severe clinical manifestations of the vegetoneurotic syndrome were evaluated in menopuasal patients after hysterectomy for uterine myoma. Favourable comprehensive effects of the drug were noted, which in most patients contributed to the elimination or significant alleviation of major vegetoneurotic, psychoemotional and metabolic-endocrine disorders. An effective combination of the estrogenic and androgenic hormonal components and their ratios, coupled with very insignificant side-effects, is an important advantage of the drug, permitting its large-scale use for the control of menopausal complications, particularly after surgery for a uterine tumour.
D002979:Climacteric / Q000187:drug effects; D003687:Dehydroepiandrosterone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D007045:Hysterectomy, Vaginal / Q000009:adverse effects; D008055:Lipids / Q000097:blood; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D009214:Myoma / Q000601:surgery*; D014594:Uterine Neoplasms / Q000601:surgery*; D014621:Vagina / Q000473:pathology; D014626:Vaginal Smears
D004338:Drug Combinations; D006065:Gonadotropins, Pituitary; D008055:Lipids; D003687:Dehydroepiandrosterone; D004958:Estradiol; C033625:Gynodian